Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 10/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23803513 | 1.00 | RIPK1 (0.50) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23819642 | 0.89 | KLK5 (0.48) | RIPK1MEN1KMT2AKLK5 | |
| SCHEMBL28616589 | 0.89 | KLK5 (0.48) | RIPK1MEN1KMT2AKLK5 | |
| SCHEMBL23819838 | 0.86 | RIPK1 (0.52) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803586 | 0.83 | RIPK1 (0.47) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803588 | 0.83 | RIPK1 (0.47) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803536 | 0.80 | RIPK1 (0.57) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803515 | 0.80 | RIPK1 (0.60) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803538 | 0.80 | RIPK1 (0.53) | RIPK1ALDH1A1LMNAPOLBHSD17B10 | |
| SCHEMBL23803540 | 0.80 | RIPK1 (0.53) | RIPK1ALDH1A1LMNAPOLBHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | SIRONAX LTD (KY) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284598-A1 | RIP1 Inhibitors | RIPK1, RIPK3, RIPK4 | RIPK1 1/4885ALDH1A1 3847/4885LMNA 1572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.